Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This study's purpose is to evaluate the long-term safety of open-label tolvaptan regimens to
determine the maximally-tolerated dose and acquire pilot efficacy data in patients with
autosomal dominant polycystic kidney disease (ADPKD).
Phase:
Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.